[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]

Turkish Journal of Cancer
1992, Volume 22, Number 4, Page(s) 133-142
[ Summary ]
CEA and CA 15-3 in the clinical follow-up of breast carcinoma
NİLÜFER GÜLER, EŞMEN BALTALI, ZEHRA KORAY, AYŞE KARS, GÜLTEN TEKUZMAN, İBRAHIM GÜLLÜ, DİNÇER FIRAT

CEA and CA 15-3 are the tumor markers used to evaluate the clinical course of patients with breast carcinoma. Levels of these markers in 103 patients with breast carcinoma who were admitted to Hacettepe University Institute of Oncology from January 1989 to June 1991 were reviewed to determine a possible correlation with the clinical course and outcome. There were 39 patients still in remission and 64 with metastatic disease at the time of evaluation. CEA levels were in the normal ranges in patients in remission (100%). In eleven of the 39 patients in remission, the CA 15-3 levels were elevated (28%, p<0.01). High CEA and CA 15-3 levels were detected in 32 and 53 out of 64 patients with metastatic disease respectively, with a rate of 50% versus 83% (p<0.01). In 23 patients with extensive metastatic disease elevated CEA levels were detected in 11 patients and CA 15-3 in 21 patients. The highest mean values of CEA were observed in patients with liver metastasis, and CA 15-3 in patients with bone metastasis. Although high CEA levels are nonspecific for and an infrequent finding in breast carcinoma, once the values are increased it must be considered to be an important clue to metastatic disease. In conclusion CA 15-3 seems to be more sensitive compared to CEA in metastatic breast carcinoma patients.

[ Summary ]
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]